TrialInvestigational new drugs2022

A phase II study of tarloxotinib (a hypoxia activated prodrug of a pan-erb tyrosine kinase inhibitor) in patients with recurrent or metastatic squamous cell carcinoma of the head and neck or skin.

Luke S McLean et al.PubMed ↗Publisher ↗

No numbers read from the abstract.